Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 4Withdrawn 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 6Thoracic 5Other hematologic neoplasm 4Genitourinary 4Head & Neck 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Small Cell Lung Carcinoma 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Extensive Stage Small Cell Lung Cancer 1

Interventions

Carboplatin 1174Cisplatin 891Pemetrexed 847pembrolizumab 626Paclitaxel 609Docetaxel 539Gemcitabine 428Radiotherapy 393Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 297durvalumab 264Drug Therapy 260osimertinib 237atezolizumab 225Radiosurgery 196Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 132Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
gossypol acetic acid × Thoracic × Clear all
NCT00934076 2015-05-08

Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer

University of Alabama at Birmingham

Phase 1 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00773955 2014-05-12

R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
15 enrolled 7 charts
Thoracic

Small Cell Lung Carcinoma

NCT00544596 2014-04-02

R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
Other solid neoplasmThoracic

Extensive Stage Small Cell Lung Cancer

NCT00544960 2010-08-27

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

Ascenta Therapeutics

Phase 2 Completed
106 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00397293 2010-08-24

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Ascenta Therapeutics

Phase 1/2 Completed
36 enrolled
Thoracic

Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡